TBC1D31 and hepatocellular carcinoma: Moreover, the TBC1D31‐amplified HCC tumors with the MAPK/ERK1/2 and PI3K/AKT hyperactivated by the TBC1D31/Rab22A/EGFR axis exhibited primary resistance to lenvatinib (Figure 7b).